LAG3基因治疗通过调控PI3K/Akt信号通路减轻自身免疫性葡萄膜炎
该研究在C57BL/6J小鼠中建立实验性自身免疫性葡萄膜炎(EAU)模型,监测LAG3表达动态,并通过玻璃体腔注射AAV2-LAG3评估治疗潜力与机制。结果显示视网膜LAG3在炎症高峰期下调,AAV2-LAG3可显著减轻临床与病理表现、恢复Th17/Treg平衡并保护血视网膜屏障完整性,其保护作用与调控PI3K/Akt通路激活相关,且可被PI3K激活剂740Y-P大幅削弱。
要点
- 视网膜LAG3表达在EAU炎症高峰期下调
- AAV2-LAG3玻璃体腔注射减轻EAU临床与病理表现
- LAG3保护作用与调控PI3K/Akt通路及恢复Th17/Treg平衡相关
核心结论
- 本研究阐明EAU中LAG3表达下调,AAV2-LAG3可能通过调控PI3K/Akt通路、恢复Th17/Treg细胞平衡和血视网膜屏障完整性来减轻疾病。
研究设计与样本
- 在C57BL/6J小鼠中通过皮下注射乳化于完全弗氏佐剂的IRBP肽并腹腔注射百日咳毒素建立EAU模型。
- 通过玻璃体腔注射给予AAV2-LAG3,采用临床评分、组织病理学分析、Evans蓝渗漏实验和透射电镜评估疾病严重程度与血视网膜屏障完整性。
- 使用qRT-PCR、western blot和RNA测序检测分子表达与信号通路,并用PI3K激活剂进行功能拯救实验。
主要发现
- 视网膜LAG3表达在EAU炎症高峰期下调。
- AAV2-LAG3给药显著减轻EAU的临床和病理表现,恢复Th17/Treg细胞平衡并保护血视网膜屏障完整性。
- RNA-seq和western blot分析提示这些保护作用与PI3K/Akt信号通路激活的调控相关。
- PI3K激活剂740Y-P应用后LAG3的保护作用大幅减弱。
关键数值与推荐
- EAU模型通过皮下给予IRBP肽(乳化于完全弗氏佐剂)并腹腔注射百日咳毒素建立。
- AAV2-LAG3通过玻璃体腔注射给药。
- PI3K激活剂740Y-P用于功能拯救实验以削弱LAG3保护作用。
临床怎么用
- AAV2-LAG3玻璃体腔注射在EAU模型中减轻疾病并保护血视网膜屏障,提示LAG3基因治疗可能成为自身免疫性葡萄膜炎的潜在策略。
- LAG3的保护作用与PI3K/Akt通路调控及Th17/Treg平衡恢复相关,提示该通路可作为机制探索方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lymphocyte-activation gene 3 (LAG3) is a critical immune checkpoint molecule, yet its role and mechanisms in autoimmune uveitis remain inadequately understood. This study sought to elucidate the expression dynamics, therapeutic potential, and molecular mechanisms of LAG3 in the context of experimental autoimmune uveitis (EAU). METHODS: The EAU model was established in C57BL/6J mice through subcutaneous administration of interphotoreceptor retinoid binding protein (IRBP) peptide emulsified in complete Freund's adjuvant and intraperitoneal injection of pertussis toxin. Alterations in LAG3 expression throughout disease progression were monitored. Adeno-associated virus serotype 2 (AAV2)-LAG3 was administered via intravitreal injection. Disease severity and blood-retinal barrier (BRB) integrity were evaluated using clinical scoring, histopathological analysis, Evans blue leakage assay, and transmission electron microscopy. Quantitative reverse-transcription PCR, western blot analysis, and RNA sequencing (RNA-seq) were utilized to examine associated molecular expression and signaling pathways. Functional rescue experiments employing a phosphoinositide 3-kinase (PI3K) activator were conducted to further explore the underlying mechanism. RESULTS: The expression of retinal LAG3 was downregulated during the peak inflammatory phase of EAU. Administration of AAV2-LAG3 significantly mitigated both clinical and pathological manifestations of EAU, re-established the Th17/Treg cell balance, and preserved the integrity of the BRB. Analyses via RNA-seq and western blotting suggested that these protective effects were associated with modulation of PI3K/Akt signaling pathway activation. Notably, the protective effects conferred by LAG3 were largely attenuated by application of the PI3K activator 740Y-P. CONCLUSIONS: This study elucidated the downregulation of LAG3 expression in EAU and suggests that AAV2-LAG3 attenuates disease, likely by regulating the PI3K/Akt pathway and restoring Th17/Treg cell balance and BRB integrity.
引用
- Zheng L, Jiang J, Zhang Q, et al. LAG3 Gene Therapy Attenuates Autoimmune Uveitis by Regulating the PI3K/Akt Signaling Pathway. Invest Ophthalmol Vis Sci. 2026. PMID: 42484593. doi:10.1167/iovs.67.8.48
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。